#meningococcal — Wednesday, May 06, 2026 (1 items)
| 0 | 💬 0 |
Immunogenicity, reactogenicity, and safety of a reduced-interval 4CMenB primary immunisation schedule in UK infants: a multicentre, open-label, assessor-blinded, phase 4 randomised controlled trial.
(linkinghub.elsevier.com)
|
Lancet Infectious Diseases 2026-05-06 | #immunogenicity #vaccination #meningococcal #safety |